GOCO vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GOCO exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. The company is experiencing a catastrophic collapse in top-line performance with YoY revenue growth plummeting -96.80% and an operating margin of -252.92%. While the stock trades at a deep discount to book value (P/B 0.45) and sales (P/S 0.08), these appear to be value traps given the trajectory of the business. Despite a bullish analyst target of $4.70, the deterministic data suggests a company in a death spiral with a -99.4% five-year price return.
JPM shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Key strengths include strong valuation and growth metrics. Price trades at a 109.8% premium to fair value estimate ($140.21), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
GOCO vs JPM: Head-to-Head Comparison
This page compares GoHealth, Inc. (GOCO) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.